{"id":65704,"date":"2025-06-30T11:08:25","date_gmt":"2025-06-30T11:08:25","guid":{"rendered":"https:\/\/biomedpharmajournal.org\/?p=65704"},"modified":"2025-07-16T05:09:16","modified_gmt":"2025-07-16T05:09:16","slug":"a-novel-analytical-method-for-simultaneous-quantification-of-bisoprolol-and-cilnidipine-by-reversed-phase-hplc-in-pure-and-tablet-dosage-form","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol18no2\/a-novel-analytical-method-for-simultaneous-quantification-of-bisoprolol-and-cilnidipine-by-reversed-phase-hplc-in-pure-and-tablet-dosage-form\/","title":{"rendered":"A Novel Analytical Method for Simultaneous Quantification of Bisoprolol and Cilnidipine by Reversed-Phase HPLC in Pure and Tablet Dosage Form"},"content":{"rendered":"

Introduction<\/strong><\/p>\n

Bisoprolol (BISO) is a cardio protective drug, prescribed for managing high blood pressure and heart failure (Figure 1). Bisoprolol reduces cardiac workload by decreasing contractility and the need for oxygen through competitive inhibition of \u03b21-adrenergic receptors.1,2<\/sup> Cilnidipine (CILN) is a calcium channel blocker, used to treat high blood pressure (Figure 2). Cilnidipine acts by blocking N-type & L-type of calcium channels which in turn dilates arterioles and venules results in reduce in blood pressure in capillary level.3,4<\/sup> The clinical applications of BISO and CILN are lowers blood pressure, reducing the chances of heart problems such as heart attack and stroke. The combination of BISO and CILN is one of the best choices in the management of hypertension.5<\/sup><\/p>\n\n\n\n
\"\"<\/td>\nFigure 1: Chemical structure of Bisoprolol<\/strong>Click here to view Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n
\"\"<\/td>\nFigure 2: Chemical structure of Cilnidipine<\/strong>Click here to view Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Extremely a very few analytical methods was established for estimation of BISO and CILN by RP-HPLC either by alone, combination or by in combination with other analytes6-9<\/sup>, which was less satisfactory levels of acceptance. The previous reported methods have lack of specificity and more retention times. The need for simultaneous quantification includes accuracy, cost-effectiveness and short run time. Hence the author aimed for development and validation of a novel and unique analytical method for Bisoprolol & Cilnidipine estimation by RP-HPLC in accordance with ICH guidelines.10-11<\/sup><\/p>\n

Materials and Methods<\/strong><\/p>\n

Chemicals and reagents<\/strong><\/p>\n

The pure analytes BISO and CILN were acquired as gift samples from Glenmark Pharmaceuticals, Mumbai. HPLC grade water, acetonitrile and trifluoro acetic acid are of Merck India made and were purchased for the preparation of mobile phase.<\/p>\n

Instrument<\/strong><\/p>\n

The proposed simultaneous analytical estimation was established and validated on auto sampler RP-HPLC (Make: Waters) connected with e2695 model pump, 2998 PDA detector and equipped with Empower 2 software.<\/p>\n

Preparation of 0.1% trifluoro acetic acid<\/strong><\/p>\n

The solution was freshly prepared by transferring 1ml of pure trifluoro acetic acid to 1000ml volumetric flask in combination with HPLC grade water and sonicated for 5min.<\/p>\n

Preparation of mobile phase<\/strong><\/p>\n

Swirl 600ml of acetonitrile, 400ml of 0.1% trifluoro acetic acid in well closed & labeled 1000ml container.<\/p>\n

Preparation of stock solution (standard)<\/strong><\/p>\n

Pure standards 25mg of BISO & 50mg of CILN were mixed and sonicated for 5min with diluent in 100ml volumetric flask before make up.<\/p>\n

Preparation of working solution (standard)<\/strong><\/p>\n

Swirl 5ml of the above solution with 30ml of diluent in volumetric flask of capacity 50ml and adjusted to the specified standard using the same diluent, label and stored. Following each preparation step, all solutions were filtered using a 0.45\u00b5m filter.<\/p>\n

Analytical method development<\/strong><\/p>\n

Selection of detection wavelength<\/strong><\/p>\n

Solution having BISO and CILN was prepared by using diluent and scanned at a region of 200 to 400nm using PDA detector. Both the drugs BISO and CILN have shown an acceptable peak response at 225nm and it was selected as common detection wavelength for both BISO and CILN throughout the analysis.<\/p>\n

Streamlined chromatographic conditions<\/strong><\/p>\n

Different trials have been performed to streamline all the vital RP-HPLC parameters as per the literature required for simultaneous determination of BISO & CILN.12-16<\/sup> Finally RP C18 column, Waters X Terra RP18 (150×4.6 mm, with a 3.5\u00b5m particle size), a mobile phase made up of 60% acetonitrile and 40% 0.1% trifluoroacetic acid is utilized, at a flow rate of 1mL\/min over an 8 minute were chosen as effective optimized RP-HPLC conditions for the projected estimation. The optimized conditions were tabulated in Table 1.<\/p>\n

Table 1: Optimized HPLC conditions of BISO and CILN<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
Column<\/strong><\/td>\nWaters X Terra RP18 <\/sub>(150×4.6mm, 3.5\u00b5)<\/td>\n<\/tr>\n
Mobile phase<\/strong><\/td>\nAcetonitrile: 0.1% trifluoro acetic acid\u00a0 (60:40 v\/v)<\/td>\n<\/tr>\n
Column temperature<\/strong><\/td>\nAmbient<\/td>\n<\/tr>\n
Flow rate<\/strong><\/td>\n1.0ml\/min<\/td>\n<\/tr>\n
Run time<\/strong><\/td>\n10mins<\/td>\n<\/tr>\n
Pumping mode<\/strong><\/td>\nIsocratic flow<\/td>\n<\/tr>\n
Injection volume<\/strong><\/td>\n10\u00b5l<\/td>\n<\/tr>\n
Wavelength<\/strong><\/td>\n225nm<\/td>\n<\/tr>\n
Retention times<\/strong><\/td>\nBisoprolol: 3.129min<\/td>\n<\/tr>\n
Cilnidipine: 6.925min<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Analytical method validation<\/strong><\/p>\n

System suitability <\/strong><\/p>\n

For assuring system performance throughout the analysis for the projected method, system suitability test was performed. The data obtained after six replicates, it was found that the results of all the system suitability parameters have shown excellent acceptability results.<\/p>\n

Selectivity <\/strong><\/p>\n

The developed method was selective, if BISO and CILN are absolutely distinguished from one another with high resolution & fixed retention times at streamlined RP-HPLC conditions. Selectivity of the suggested process was analyzed by six frequent injections of standard solutions (working) containing BISO and CILN.<\/p>\n

Specificity <\/strong><\/p>\n

The justification for examine specificity was to establish interfering peaks from impurities or degradants or from excipients of formulation or placebo at same retention times with the analytes of concern. In this method tablet extract, placebo, standard drug solutions & mobile phase (blank injection) were injected to check the specificity of method.<\/p>\n

Linearity <\/strong><\/p>\n

A blank solution of diluent and six different standard drug solutions containing 2.52\u00b5g\/ml to 37.80\u00b5g\/ml of BISO and 5.0\u00b5g\/ml to 75.0\u00b5g\/ml of CILN were equipped with diluent exactly & injected into optimized RP-HPLC process. Using peak responses of respective concentrations calibration plots were constructed. From the calibration plots linearity, range and r2<\/sup> values were calculated.<\/p>\n

Accuracy <\/strong><\/p>\n

To identify accuracy of the planned RP-HPLC system, standard addition technique was adopted. Solutions in 3 concentration levels containing BISO (12.5mg, 25.0mg & 37.8mg) and CILN (25.0mg, 50.0mg & 75.0mg) were prepared and the triplicate injections from each level was injected in to RP-HPLC.<\/p>\n

Precision<\/strong><\/p>\n

System precision <\/strong><\/p>\n

It was identified through 6 times continually injecting recently equipped working standard solution containing 25\u03bcg\/ml of BISO & 50\u03bcg\/ml of CILN into RP-HPLC system and evaluated for the %RSD of peak areas.<\/p>\n

Method precision <\/strong><\/p>\n

To compute the method precision of projected analytical method, sample solution attains with 25\u03bcg per milli litre of BISO & 50\u03bcg per milli litre of CILN was continuously injected for 6 times into RP-HPLC system & computed for the %RSD of drug estimated.<\/p>\n

Intermediate precision (Ruggedness) <\/strong><\/p>\n

Six samples of same batch containing 25\u03bcg\/ml of BISO and 50\u03bcg\/ml of CILN were evaluated to prove intermediate precision of the projected analytical process by various analysts on various columns and by various instruments. From resultant chromatograms of analyte and its %RSD was tabulated.<\/p>\n

Robustness<\/strong><\/p>\n

To verify the robustness of the anticipated analytical technique, one out of optimized chromatographic parameters was deliberately changed and the assay was performed. During the validation process rate of flow was tuned to \u00b10.2ml\/min and organic component of the mobile phase was adjusted to \u00b110% & resulting changes occurred in chromatograms after injecting sample solutions in triplicates comprising 25\u03bcg\/ml of BISO and 50\u03bcg\/ml of CILN.<\/p>\n

LOD and LOQ<\/strong><\/p>\n

The expressions LOD & LOQ are elaborated as detection of smallest amount of analyte and quantification of smallest amount of analyte, by projected analytical method. According to ICH guidelines, signal to noise ratio method is one of the recognized methods to evaluate LOD and LOQ. Triplicates of lowest concentrations of standard solutions (working) & blank solutions of BISO and CILN were analyzed to estimation LOD & LOQ of the method at optimized RP-HPLC conditions.<\/p>\n

Assay of BISO and CILN in marketed formulation<\/strong><\/p>\n

From 20 marketed formulations (tablets), average weight of each one tablet was tabulated and grinded to fine powder. Tablet powder equivalent to 25mg and 50mg of BISO and CILN respectively was shifted to 100ml volumetric flask & swirl with 75ml diluent, sonicated for 5min, filled with the same diluent and passed through a 0.45 \u00b5m filter paper. A 5 milli litre portion of the stock filtrate was diluted to a total volume of 50 milli litre with the diluent. RP-HPLC chromatographic system was then used to inject replicates and obtain peak areas from chromatograms to determine the amounts of BISO and CILN in each tablet.<\/p>\n

Stress<\/strong> degradation studies<\/strong><\/p>\n

A stability stock solution for stress degradation studies was arranged by combining 200mg of formulation powder containing BISO and CILN with 70ml of diluent in a volumetric flask of capacity 100ml. The blend underwent sonication for 15 minutes, diluted to mark using similar diluent, did go through a 0.45\u00b5m filter.<\/p>\n

Acid induced degradation<\/strong><\/p>\n

5ml of stability stock filtrate, 1ml of 1N HCl and 30ml of diluent were mixed in volumetric flask of capacity 50ml, solution was transferred to water bath at constant temperature of 60\u00b0C for 30 minutes. After cooling, 1 mL of 1N NaOH was introduced, and solution was adjusted to final volume with diluent. It was then stored at room temperature and injected after 24 hours.<\/p>\n

Alkali induced degradation<\/strong><\/p>\n

5ml of stability stock filtrate, 1ml of 1N NaOH and 30ml of diluent were mixed in volumetric flask of capacity 50ml, solution was transferred to water bath at constant temperature of 60\u00b0C for 30 minutes. After cooling, 1 ml of 1N HCl was introduced, and solution was adjusted to final volume with diluent. It was then stored at room temperature and injected after 24 hours.<\/p>\n

Peroxide induced degradation<\/strong><\/p>\n

5ml of stability stock filtrate, 1ml of 30% H2<\/sub>O2<\/sub> & 30ml of diluent were mixed in volumetric flask of capacity 50ml, solution was transferred to water bath at constant temperature of 60\u00b0C for 30 minutes. After cooling, solution was diluted to mark with diluent, stored at room temperature, and then injected after 24 hours.<\/p>\n

Thermal induced degradation<\/strong><\/p>\n

The sample powder containing BISO and CILN was exposed at 105\u00b0C for 72hrs. 200mg of sample was weighed and transferred into 100ml volumetric flask with 70ml of diluent. The mixture was sonicated for 15 minutes, then diluted to mark with same diluent, mixed, and filtered through a 0.45\u00b5m filter. Next, 5ml of filtrate was diluted to 50ml with diluent, mixed, stored at room temperature and injected into RP-HPLC system after 24 hours.<\/p>\n

Photolytic degradation<\/strong><\/p>\n

The sample powder was directly exposed under UV light for 24hrs. 200mg of this sample was weighed and transferred into 100ml volumetric flask containing 70ml of diluent and sonicated for 15min and diluted to the mark with the same diluent, mixed and was passed through 0.45\u00b5 filter. Further 5ml filtrate was diluted to 50ml with diluent, mixed, stored at room temperature and injected into RP-HPLC system after 24hrs. All the degradation samples passed through 0.45\u00b5 filter before injected in to RP-HPLC system.<\/p>\n

Stability studies<\/strong><\/p>\n

To identify the stability of projected analytical method, test solution consisting of 25\u00b5g\/ml BISO and 50\u00b5g\/ml CILN was prepared freshly, passed through 0.45\u00b5 filter and the filtrate was injected into RP-HPLC system at different and standard time intervals (0hrs, 6hrs, 12hrs, 18hrs & 24hrs).<\/p>\n

Results <\/strong><\/p>\n

Analytical method validation<\/strong><\/p>\n

System suitability<\/strong><\/p>\n

Projected RP- High-Performance Liquid Chromatography method passes the system suitability test for estimation of BISO and CILN, as the resolution (Rs) was >2, total theoretical plate count (N) was >2000, peak tailing factor (Tf) was <2 & the %RSD of peak areas was <2. The results were furnished in Table 2.<\/p>\n

Table 2: System suitability results of BISO and CILN<\/strong><\/p>\n\n\n\n\n\n
Analyte<\/strong><\/td>\nRt (min.)<\/strong><\/td>\n%RSD peak areas<\/strong><\/td>\nUSP plate count<\/strong><\/td>\nUSP tailing<\/strong><\/td>\nResolution<\/strong><\/td>\n<\/tr>\n
BISO<\/td>\n3.129<\/td>\n0.3<\/td>\n4662.67<\/td>\n1.05<\/td>\n–<\/td>\n<\/tr>\n
CILN<\/td>\n6.925<\/td>\n0.3<\/td>\n12144.8<\/td>\n0.95<\/td>\n16.99<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Selectivity<\/strong><\/p>\n

The chromatographic data on inspection it was establish that the retention times & resolution of analytes was fixed with adequate change, confirms selectivity of projected analytical technique. The typical chromatogram of BISO and CILN were shown in Figure 3.<\/strong><\/p>\n\n\n\n
\"\"<\/td>\nFigure 3: Typical chromatogram of Bisoprolol and Cilnidipine<\/strong>Click here to view Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Specificity<\/strong><\/p>\n

No interfering peaks or no additional peaks were viewed in the chromatograms except BISO and CILN peaks, with all the injected solutions. Thus it indicates that projected RP-HPLC system was specific to recognize BISO & CILN only.<\/p>\n

Linearity<\/strong><\/p>\n

By the new recommended RP-HPLC method BISO has shown linearity 2.52\u00b5g\/ml to 37.80\u00b5g\/ml with relevant regression equation y=43555x+2627.63 and CILN has shown linearity 5.00-75.00\u00b5g\/ml with relevant regression equation y=63276x+34138. The values for r\u00b2 for BISO and CILN were 0.9995 and 0.9996 respectively. The calibration curves of BISO and CILN were shown in Figure 4 & Figure 5 and the data on linearity has been presented in Table 3.<\/p>\n\n\n\n
\"\"<\/td>\nFigure 4: Linearity curve of BISO<\/strong>Click here to view Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n
\"\"<\/td>\nFigure 5: Linearity curve of CILN<\/strong>Click here to view Figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Table 3: Linearity data of BISO and CILN<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Injection<\/strong><\/td>\nBISO<\/strong><\/td>\nCILN<\/strong><\/td>\n<\/tr>\n
Concentration (micrograms per milliliter)<\/strong><\/td>\nPeak area<\/strong><\/td>\nConcentration (micrograms per milliliter)<\/strong><\/td>\nPeak area<\/strong><\/td>\n<\/tr>\n
Blank<\/td>\n00.00<\/td>\n000000<\/td>\n00.00<\/td>\n000000<\/td>\n<\/tr>\n
Linearity 1<\/td>\n02.52<\/td>\n104895<\/td>\n05.00<\/td>\n424515<\/td>\n<\/tr>\n
Linearity 2<\/td>\n06.30<\/td>\n274526<\/td>\n12.50<\/td>\n814575<\/td>\n<\/tr>\n
Linearity 3<\/td>\n12.60<\/td>\n558347<\/td>\n25.00<\/td>\n1627484<\/td>\n<\/tr>\n
Linearity 4<\/td>\n25.20<\/td>\n1112478<\/td>\n50.00<\/td>\n3244563<\/td>\n<\/tr>\n
Linearity 5<\/td>\n31.50<\/td>\n1392594<\/td>\n62.50<\/td>\n4045894<\/td>\n<\/tr>\n
Linearity 6<\/td>\n37.80<\/td>\n1624456<\/td>\n75.00<\/td>\n4865436<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Accuracy<\/strong><\/p>\n

Individual recoveries of all the levels of BISO and CILN were within the permitted limit. The mean %recoveries of BISO and CILN are 99.56% and 100.35% respectively and the study confirms the accuracy of the suggested RP-HPLC system. The data related to accuracy are summarized in Table 4.<\/p>\n

Table 4: Accuracy results of BISO and CILN<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
Levels<\/strong><\/td>\nBISO<\/strong><\/td>\nCILN<\/strong><\/td>\n<\/tr>\n
Found conc. (mg)<\/strong><\/td>\nMean %recovery \u00b1SD<\/strong><\/td>\nFound conc. (mg)<\/strong><\/td>\nMean %recovery \u00b1SD<\/strong><\/td>\n<\/tr>\n
50%<\/td>\n12.29<\/td>\n98.5\u00b10.28<\/td>\n25.05<\/td>\n100.27\u00b10.06<\/td>\n<\/tr>\n
100%<\/td>\n25.32<\/td>\n101.0\u00b10.49<\/td>\n50.32<\/td>\n100.48\u00b10.16<\/td>\n<\/tr>\n
150%<\/td>\n37.16<\/td>\n99.2\u00b10.55<\/td>\n75.23<\/td>\n100.31\u00b10.02<\/td>\n<\/tr>\n
Mean %recovery<\/td>\n99.56<\/td>\n<\/td>\n100.35<\/td>\n<\/tr>\n
Mean\u00b1SD<\/td>\n1.18<\/td>\n0.13<\/td>\n<\/tr>\n
%RSD<\/td>\n1.2<\/td>\n0.1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/strong>Precision<\/strong><\/p>\n

System precision<\/strong><\/p>\n

The %RSD of peak areas from six replicate injections of the working standard solution was 0.41% for BISO and 0.14% for CILN. This demonstrates that the system precision is within acceptable limits.<\/p>\n

Method precision<\/strong><\/p>\n

The mean of analyte calculated and its %RSD of 6 replicate injections of sample solutions was identified as 100.03% % & 0.4% for BISO; 100.08% & 0.3% for CILN. Therefore, the projected method was reproducible.<\/p>\n

Intermediate precision (Ruggedness)<\/strong><\/p>\n

The mean assay of analytes & their %RSD were calculated as 99.98% & 0.4% for BISO; 100.2% & 0.3% for CILN respectively. Hence, the projected RP-HPLC method was reproducible with different instrument by different analyst and on different column. The precision data was tabulated in Table 5.<\/p>\n

Table 5: Precision results of BISO and CILN<\/strong><\/p>\n\n\n\n\n\n\n\n
Analyte<\/strong><\/td>\nSystem precision<\/strong><\/td>\nMethod precision<\/strong><\/td>\nIntermediate precision<\/strong><\/td>\n<\/tr>\n
BISO<\/strong><\/td>\nMean\u00b1SD<\/td>\n1128268\u00b13348.61<\/td>\n100.03%\u00b10.44<\/td>\n99.98%\u00b10.39<\/td>\n<\/tr>\n
%RSD<\/td>\n0.3%<\/td>\n0.4%<\/td>\n0.4%<\/td>\n<\/tr>\n
CILN<\/strong><\/td>\nMean\u00b1SD<\/td>\n3224623\u00b19773.93<\/td>\n100.08%\u00b10.37<\/td>\n100.2%\u00b10.25<\/td>\n<\/tr>\n
%RSD<\/td>\n0.3%<\/td>\n0.3%<\/td>\n0.3%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/strong>Robustness<\/strong><\/p>\n

From the results it was found that the proposed analytical method was stable even after small but deliberate changes in the flow rate and the composition ratio of the mobile phase. It was pragmatic that there was slight change in system suitability parameters but net assay values of BISO and CILN were within the acceptable limits. The robustness data was reflected in Table 6.<\/p>\n

Table 6: Robustness results of BISO and CILN<\/strong><\/p>\n\n\n\n\n\n\n\n\n
Conditions<\/strong><\/td>\nBISO<\/strong><\/td>\nCILN<\/strong><\/td>\n<\/tr>\n
Rt (min.)<\/strong><\/td>\nPlate count<\/strong><\/td>\n%Drug found<\/strong><\/td>\nRt (min.)<\/strong><\/td>\nPlate count<\/strong><\/td>\nRs<\/strong><\/td>\n%Drug found<\/strong><\/td>\n<\/tr>\n
0.8ml\/min<\/td>\n3.95<\/td>\n6444<\/td>\n99.73<\/td>\n8.85<\/td>\n9968<\/td>\n19.33<\/td>\n100.63%<\/td>\n<\/tr>\n
1.2ml\/min<\/td>\n2.65<\/td>\n3456<\/td>\n100.27<\/td>\n5.76<\/td>\n10346<\/td>\n15.22<\/td>\n99.83%<\/td>\n<\/tr>\n
27:73v\/v<\/td>\n3.94<\/td>\n6168<\/td>\n99.80<\/td>\n8.72<\/td>\n14256<\/td>\n19.04<\/td>\n100.67%<\/td>\n<\/tr>\n
33:67v\/v<\/td>\n2.73<\/td>\n3656<\/td>\n99.20<\/td>\n5.05<\/td>\n8867<\/td>\n11.40<\/td>\n100.00%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/strong>LOD and LOQ<\/strong><\/p>\n

The estimated limit of detection (LOD) & limit of quantitation (LOQ) values for BISO were 0.025\u00b5g\/ml & 0.075\u00b5g\/ml respectively; for CILN the LOD & LOQ are 0.050\u00b5g\/ml & 1.50\u00b5g\/ml respectively. The LOD & LOQ data was tabulated in Table 7.<\/p>\n

Table 7: LOD & LOQ results of BISO and CILN<\/strong><\/p>\n\n\n\n\n\n
Analyte<\/strong><\/td>\nLOD<\/strong><\/td>\nLOQ<\/strong><\/td>\n<\/tr>\n
BISO<\/strong><\/td>\n0.025\u00b5g\/ml<\/td>\n0.075\u00b5g\/ml<\/td>\n<\/tr>\n
CILN<\/strong><\/td>\n0.050\u00b5g\/ml<\/td>\n0.150\u00b5g\/ml<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/strong>Assay of BISO and CILN in tablets<\/strong><\/p>\n

Assay result reveals that each tablet of BESICOR-C contains 5.03mg and 9.92mg of BISO and CILN respectively against its label claim with the projected analytical method. The assay data was furnished in Table 8.<\/p>\n

Table 8: Assay results for marketed tablet of BISO and CILN<\/strong><\/p>\n\n\n\n\n\n
Brand name<\/strong><\/td>\nDrugs<\/strong><\/td>\nLabel claim (mg)<\/strong><\/td>\nAmount recovered (mg)<\/strong><\/td>\nAssay<\/strong><\/td>\n<\/tr>\n
BESICOR-C<\/strong><\/td>\nBisoprolol<\/td>\n5.00<\/td>\n5.03<\/td>\n100.60%<\/td>\n<\/tr>\n
Cilnidipine<\/td>\n10.00<\/td>\n9.92<\/td>\n99.20%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0<\/strong>Forced degradation studies<\/strong><\/p>\n

1N HCl originated degradation was calculated as 21.50% and 24.00%; 1N NaOH stimulated degradation was 19.20% and 22.10%; while 30% H2<\/sub>O2<\/sub> stimulated degradation was 15.60% and 17.00% for BISO and CILN respectively. thermal affected degradation at 105\u00b0C was 17.40% and 16.70% and Photolytic degradation under UV light was 15.70% and 13.90% for BISO and CILN respectively. The forced degradation study data was given in Table 9.<\/p>\n

Table 9: Forced degradation results of BISO and CILN<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
Conditions<\/strong><\/td>\nBISO<\/strong><\/td>\nCILN<\/strong><\/td>\n<\/tr>\n
% of degradation<\/strong><\/td>\nPurity angle<\/strong><\/td>\nPurity threshold<\/strong><\/td>\n% of degradation<\/strong><\/td>\nPurity angle<\/strong><\/td>\nPurity threshold<\/strong><\/td>\n<\/tr>\n
Control<\/td>\n–<\/td>\n2.064<\/td>\n45.365<\/td>\n–<\/td>\n15.214<\/td>\n52.647<\/td>\n<\/tr>\n
1N HCl<\/td>\n21.50<\/td>\n2.041<\/td>\n44.256<\/td>\n24.00<\/td>\n15.212<\/td>\n52.546<\/td>\n<\/tr>\n
1N NaOH<\/td>\n19.20<\/td>\n2.042<\/td>\n45.268<\/td>\n22.10<\/td>\n15.142<\/td>\n52.461<\/td>\n<\/tr>\n
30% H2<\/sub>O2<\/sub><\/td>\n15.60<\/td>\n2.037<\/td>\n48.252<\/td>\n17.00<\/td>\n15.152<\/td>\n52.314<\/td>\n<\/tr>\n
Thermal<\/td>\n17.40<\/td>\n2.034<\/td>\n45.198<\/td>\n16.70<\/td>\n15.134<\/td>\n52.394<\/td>\n<\/tr>\n
Photolytic<\/td>\n15.70<\/td>\n2.026<\/td>\n45.367<\/td>\n13.90<\/td>\n15.291<\/td>\n52.471<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Stability studies<\/strong><\/p>\n

The calculated %drug available after 24hrs was 98.3% for BISO and 97.6% for CILN. The stability study data was tabulated in Table 10.<\/p>\n

Table 10: Stability study results of BISO and CILN<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n
Injection No.<\/strong><\/td>\nTime in hrs <\/strong><\/td>\nBISO<\/strong><\/td>\nCILN<\/strong><\/td>\n<\/tr>\n
% of drug found<\/strong><\/td>\n% of drug found<\/strong><\/td>\n<\/tr>\n
1<\/td>\nInitial<\/td>\n100.2<\/td>\n100.6<\/td>\n<\/tr>\n
2<\/td>\n6hrs<\/td>\n99.8<\/td>\n100.3<\/td>\n<\/tr>\n
3<\/td>\n12hrs<\/td>\n99.5<\/td>\n100.5<\/td>\n<\/tr>\n
4<\/td>\n18hrs<\/td>\n98.5<\/td>\n98.8<\/td>\n<\/tr>\n
5<\/td>\n24hrs<\/td>\n98.3<\/td>\n97.6<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Discussion<\/strong><\/p>\n

In the proposed method, the retention time of Bisoprolol and Cilnidipine was found to be 3.129min and 6.925min respectively. Quantification was linear in concentration range of 2.52-37.80\u00b5g\/ml for Bisoprolol and 5.0-75.0\u00b5g\/ml for Cilnidipine. The regression equation of the linearity plot of concentration of Bisoprolol and Cilnidipine over its peak area was found to be<\/p>\n

y=43555x+2627.63 (r2<\/sup>=0.9995) for Bisoprolol and y=63276x+34138 (r2<\/sup>=0.9996) for Cilnidipine, where x is the concentration of Bisoprolol and Cilnidipine (\u00b5g\/ml) and y is the corresponding peak area. The number of theoretical plates calculated was 4662.67 for Bisoprolol and 12144.8 for Cilnidipine and tailing factor was 1.05 for Bisoprolol and 0.95 for Cilnidipine, which indicates efficient performance of the column. The limit of detection and limit of quantification for Bisoprolol were found to be 0.025\u00b5g\/ml and 0.075\u00b5g\/ml and for Cilnidipine were found to be 0.050\u00b5g\/ml and 0.150\u00b5g\/ml respectively, which indicate the sensitivity of the method. The use of acetonitrile and 0.1% trifluoro acetic acid in the ratio of 60:40 v\/v as mobile phase resulted in peak with good shape and resolution. The high percentage of recovery indicates that the proposed method is highly accurate. No interfering peaks were found in the chromatogram of the formulation within the run time indicating that excipients used in tablet formulations did not interfere with the estimation of the drug by the proposed HPLC method.<\/p>\n

Conclusion<\/strong><\/p>\n

After extensive study by author, a novel, economical, most stable and effective reversed-phase HPLC method was designed and validated using unique optimized chromatographic conditions than previous studies for estimation of Bisoprolol and Cilnidipine in tablets. Validation report provides evidence that the system was suitable, robust, accurate, linear, rugged & precise projected analytical method even in presence of degradation products up till 24hrs. The proposed HPLC method can be reliably adopted for routine quality control analysis of Bisoprolol and Cilnidipine in its tablet dosage forms.<\/p>\n

Acknowledgement<\/strong><\/p>\n

The authors are very grateful to Nizam Institute of Pharmacy, Deshmukhi, Telangana for proving necessary support for carryout the research work.<\/p>\n

Funding Sources<\/strong><\/p>\n

The author(s) received no financial support for the research, authorship, and\/or publication of this article.<\/p>\n

Conflict of Interest<\/strong><\/p>\n

The author(s) do not have any conflict of interest.<\/p>\n

Data Availability Statement<\/strong><\/p>\n

This statement does not apply to this article.<\/p>\n

Ethics Statement<\/strong><\/p>\n

This research did not involve human participants, animal subjects, or any material that requires ethical approval.<\/p>\n

Informed Consent Statement<\/strong><\/p>\n

This study did not involve human participants, and therefore, informed consent was not required.<\/p>\n

Clinical Trial Registration<\/strong><\/p>\n

This research does not involve any clinical trials<\/p>\n

Permission to reproduce material from other sources<\/strong><\/p>\n

Not applicable<\/p>\n

Author Contributions<\/strong><\/p>\n